FACT
Facet Biotech Corporation
FACT is defunct.
  • Mar. 9, 2010, 5:21 PM

    Facet Biotech (FACT) resumes trading and jumps 66.2% to $27 - the per-share price that Abbott Labs (ABT) has agreed to pay for the company in a deal for a net $450M.

    | Mar. 9, 2010, 5:21 PM
  • Mar. 9, 2010, 4:58 PM

    Abbott Labs (ABT) shores up its early and midstage pipeline with an agreement to acquire Facet Biotech (FACT) for $27/share in cash, for a net value of about $450M. FACT halted at $16.37 and will resume trading at 5:20 p.m EST.

    | Mar. 9, 2010, 4:58 PM
  • Dec. 10, 2009, 9:50 AM

    Facet Biotech (FACT) says Biogen Idec's (BIIB) increased bid of $17.50/share is still too low, and not in shareholders' best interest. Facet notes other parties have also expressed interest in the company and its assets, and that it is allowing them, along with Biogen, to conduct due diligence.

    | Dec. 10, 2009, 9:50 AM
  • Dec. 10, 2009, 9:00 AM

    Premarket gainers: ONTY +10%. ING +4%. APC +4%. NLST +3%. FACT +3%. BCS +3%. IOC +3%. GFI +3%.
    Losers: SIGA -13%. IT -8%. CIEN -3%. LLY -3%.

    | Dec. 10, 2009, 9:00 AM
  • Dec. 3, 2009, 5:26 PM

    Biogen Idec (BIIB) hikes its bid for Facet Biotech (FACT) to a "best and final offer" of $17.50 a share, a 21% increase from its unsolicited Sept. 4 offer, and a 98% premium to Facet's closing price then. FACT -2.8% AH, to $16.75.

    | Dec. 3, 2009, 5:26 PM
  • Oct. 16, 2009, 4:37 PM
    Biogen Idec (BIIB) says it's extending its hostile $14.50/share offer for Facet Biotech (FACT) to Dec. 16, from an original expiration of Oct. 19. FACT closed +0.6%, at $18.03.
    | Oct. 16, 2009, 4:37 PM
  • Sep. 8, 2009, 8:07 AM
    Facet Biotech (FACT) rejects Biogen Idec's (BIIB) $14.50/share bid, calling it inadequate. Says BIIB's decision to launch a bid for Facet within weeks of their joint decision to begin a Phase III trial for its daclizumab MS treatment "does not appear to be a coincidence."
    | Sep. 8, 2009, 8:07 AM
  • Sep. 4, 2009, 11:22 AM
    Facet Biotech (FACT -0.3%) shares halted at $8.79 as Biogen Idec (BIIB +0.9%) offers $14.50 a share for the company, valuing the deal at $346.6M.
    | Sep. 4, 2009, 11:22 AM